Detalhe da pesquisa
1.
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Cancer Immunol Immunother
; 71(4): 865-874, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462870
2.
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.
J Transl Med
; 19(1): 270, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34167578
3.
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
Acta Oncol
; 60(10): 1317-1324, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282710
4.
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cancer Immunol Immunother
; 69(11): 2209-2221, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474768
5.
Response to cabozantinib in renal cell carcinoma with cardiac metastases.
Anticancer Drugs
; 31(3): 314-318, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31929349
6.
Facing SARS-CoV-2 outbreak in immunotherapy era.
Future Oncol
; 16(20): 1475-1485, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468851
7.
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description.
Hepatobiliary Pancreat Dis Int
; 21(1): 86-89, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33637455
8.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489861
9.
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Lung Cancer
; 187: 107444, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38157806
10.
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.
Curr Oncol
; 30(2): 2366-2387, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36826142
11.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Front Oncol
; 13: 1125013, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895480
12.
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion.
J Thorac Oncol
; 18(5): 576-586, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36646211
13.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042716
14.
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.
Cancers (Basel)
; 14(10)2022 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35626040
15.
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Thorac Cancer
; 13(3): 483-488, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34939342
16.
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
J Hematol Oncol
; 15(1): 9, 2022 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35062993
17.
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Eur J Cancer
; 150: 224-231, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934059
18.
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Eur J Cancer
; 148: 24-35, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721704
19.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Thorac Cancer
; 12(6): 880-889, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33527756
20.
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
J Immunother Cancer
; 9(4)2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827906